Most influential people in biopharma—the scientists UnitedHealth was this quarter's most profitable payer—again J&J axes Bavarian Nordic pact for HPV and Hep B vax, keeps two other programs Insulet to swap CEOs amid Omnipod 5 insulin pump rollout Seagen CEO Clay Siegall put on leave amid domestic violence investigation Cerebral under federal investigation for possible violations of controlled substances law LogicBio's sun and shares rise again after FDA releases clinical hold on pediatric genome editing therapy Emulate upgrades intestinal organ-on-a-chip for exploring inflammatory bowel disease Intra-Cellular sees the 'hope and the light' as it kick-starts new Caplyta bipolar campaign Scientists may have inadvertently discovered how to reverse a central protein pitfall that causes dementia 340B hospitals amplify loss projections as more drugmakers unveil restrictions Biomanufacturing player eureKING emerges with star-studded roster of Sanofi, Bayer vets in tow CAR-NK cell therapy extends survival in pancreatic cancer mouse model, CytoImmune plans 2022 trial Featured Story | By Eric Sagonowsky,Kevin Dunleavy,Max Bayer,Andrea Park,Gabrielle Masson Without science, biopharma wouldn't exist. Without new, groundbreaking science, it might exist, but it wouldn't be very exciting—and it certainly wouldn't be a trillion-dollar enterprise. That's why our look at this year's most influential people had to turn to scientists next. read more |
| |
|---|
|
Top Stories By Paige Minemyer Each of the six major national payers exceeded Wall Street's expectations for profit in the first quarter, with UnitedHealth Group out in front as the most profitable company. read more By Max Bayer J&J is taking the cleaver to its Bavarian Nordic-partnered HPV and hepatitis B programs, both of which had yet to produce clinical assets. But the Big Pharma is still holding onto its HIV and Ebola collaborations. read more By Conor Hale Shacey Petrovic, who served as Insulet’s president and chief executive since 2019, will be stepping down June 1 for personal family reasons. She will be replaced by ResMed's Jim Hollingshead. read more By Angus Liu Seagen’s co-founder Clay Siegall, Ph.D., has been put on a leave of absence after an alleged incident of domestic violence that happened at his home. read more By Heather Landi Mental health startup Cerebral said Saturday it is under investigation by the Department of Justice for "possible violations" of the Controlled Substances Act. "To be clear, at this time, no regulatory or law enforcement authority has accused Cerebral of violating any law," the company said in a statement. read more By Annalee Armstrong The sun and shares are rising again at LogicBio after the FDA lifted a clinical hold on a gene editing therapy for children with a rare disorder. Shares of the Lexington, Masschusetts-based biotech were sent skyward by 60% as the markets opened Monday morning. read more By Conor Hale The chips create a living replica of the cells that make up the walls of the human colon and its surrounding blood vessels. read more By Ben Adams Intra-Cellular rolled out its first bipolar ad campaign for Caplyta after nabbing a new FDA approval for the condition at the end of last year. read more By Max Bayer A global team of scientists may have inadvertently discovered a potential treatment for one of the root causes of dementia. The researchers say when under stress, the endoplasmic reticulum actually reversed the build-up of protein "aggregates" caused by misfolding, a mechanism that can result in neurodegenerative diseases. read more By Dave Muoio Three months after its prior survey, 340B Health saw hospitals more than double their expected losses in response to new restrictions from major drugmakers. Many program participants also outlined recent access issues and potential threats to their operations. read more By Fraiser Kansteiner eureKING—which is billing itself as Europe's first biomanufacturing-focused special-purpose acquisition company (SPAC)—launched Monday with plans to trade on the Euronext Paris exchange and raise €150 million ($158 million) to gobble up companies in the continent's CDMO scene read more By Kyle LaHucik Using natural killer cells from umbilical cords, City of Hope showed that a CAR-NK cell therapy was able to boost length of survival in a mouse model of pancreatic cancer using a freezing and thawing method. CytoImmune Therapeutics is slated to test the therapy in humans later this year. read more |
